Cipla Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/css57h8rdqowb36g5fz523oz.pdf

Key Takeaways


The $1 Billion U.S. Exit Rate: Pathways and Dependencies

Achin Gupta: "We have different pathways to get there. And therefore, we are maintaining the same guidance at this point in time."

India Business: Chronic Strength, GLP-1 Momentum

Achin Gupta: "We are seeing month-on-month growth rates of somewhere between 5% to 10%. So we expect that trajectory to continue. Yurpeak has become the second largest brand in the rankings on GLP. And I think we don't expect any saturation on this front."

Respiratory Franchise: Barriers, Approvals, and the Symbicort Question

Achin Gupta: "Respiratory is a complex opportunity, which as per the FDA classification also it is, right? So there are entry barriers and therefore, it typically remains a fewer player market... it is typically not a very high competitive commodity generic market."

Margins: Sequential Expansion on Track


Pipeline Beyond Respiratory: Biosimilars, Peptides, and Complex Generics


Regional Markets: South Africa Reset, EMEU Resilience

Achin Gupta: "We evaluate a lot. We're just being selective so that we make the right moves, which will help the business grow from a longer-term window as well."

Guidance & Commitments

CommitmentSpecificsTimeline
U.S. exit run rate$1 billion annualized revenue run rateFY27 exit
U.S. launches3 additional significant launches: 2 respiratory assets, 1 peptideFY27
Generic Advair launchLaunch and begin revenue buildQ3 FY27
Ventolin supply rampExponential increase from current levels to capture much higher share of ~2.4 crore unit marketThrough FY27
EBITDA margin18.5%–20% full-year band; sequential expansion in remaining quarters, with Q4 improving over Q3FY27
R&D spend6%–7% of revenueFY27
U.S. pipeline filings45–50 complex filings for North AmericaNext 3 years
Pembrolizumab biosimilar filingFile for approval, targeting first-wave launchFile next year; launch ~2029
Biosimilar pipeline additionsAdd 1–2 assets internally each year plus selective in-licensingOngoing
LanreotideNot contributing this financial year; two parallel paths pursuedBeyond FY27

Key Metrics

MetricQ2 FY27
Revenue₹7,404 cr, +4% QoQ
One India revenue growth12% YoY
Branded prescription growth15% (IQVIA YTD Sep '26)
EBITDA margin (excl. other income)18.7%, +200 bps QoQ
Gross margin after material costs64.4%, +7% QoQ
Total expenses₹3,382 cr, +4% QoQ
R&D spend₹423 cr, 5.7% of revenue
Profit after tax₹878 cr, 11.9% of sales, +77 bps QoQ
Effective tax rate27.2%
North America quarterly revenue$172 mn, +$10 mn QoQ
EMEU quarterly revenue$101 mn
U.S. Albuterol MDI market share22% (IQVIA, last week of Sep '26)
South Africa private market secondary growth6.5% vs market 5% (IQVIA MAT Aug '26)
Chronic portfolio mix60.3% (IQVIA MAT Sep '26)
Net cash balance₹9,823 cr as of 30 Sep '26
Debt (incl. lease liabilities)₹699 cr as of 30 Sep '26
Full-year EBITDA margin guidance18.5% to 20%, maintained
Full-year R&D spend guidance6% to 7% of revenue
Full-year ETR guidance27% to 27.5%
U.S. exit run rate guidance$1 bn annualized, maintained
U.S. filings target45 to 50 over next 3 years, vs ~10 average previously
Biosimilar assets under development4
Trade generics YoY growthMid-single digits
India branded prescription H1 FY27 growth14.6% vs market 14.3%
GLP-1 portfolio share of domestic sales~10% (per an analyst's statement)